Aegis Capital

Aegis Capital Corp.

Aegis Capital Corp. is a New York-based broker-dealer combining wealth management with investment banking. Its equity research covers a short list of companies, most of them its investment banking clients.

Company history

Robert Eide founded Aegis in New York in 1984; it serves private clients, institutions and corporations with brokerage, wealth management, investment banking and equity research. Regulators have sanctioned it several times: FINRA fined it $950,000 in 2015 over unregistered penny-stock sales, the SEC and FINRA imposed $1.3 million in 2018 for anti-money-laundering failures, and FINRA fined it $1.05 million in 2021 over supervision of excessive trading.

  1. 1984Founded in New York by Robert Eide
  2. 2015FINRA fines firm $950,000 over unregistered penny-stock sales
  3. 2018Pays $1.3 million to SEC and FINRA over AML failures
  4. 2021FINRA fines firm $1.05 million over excessive-trading supervision

Research

Ratings are Buy, Hold and Sell, defined by whether the share price adequately reflects a company's prospects over 12–18 months. As of April 2026, about 96% of rated stocks carried a Buy, and 77% of those were investment banking clients.

Coverage12M

Stocks
1
Ratings
1
Price targets
0
Upgrades
0
Downgrades
0
Initiations
0
Reiterations
1
  • Positive100%1
  • Neutral0%0
  • Negative0%0

Sectors

  • Health Care100%

Ratings

  • Buy100%

Listing

  • Canada100%

Activity24M

RatingsPrice targets1
Oct 2024 · Ratings 0 · Price targets 0Nov 2024 · Ratings 0 · Price targets 0Dec 2024 · Ratings 1 · Price targets 0Jan 2025 · Ratings 0 · Price targets 0Feb 2025 · Ratings 0 · Price targets 0Mar 2025 · Ratings 0 · Price targets 0Apr 2025 · Ratings 0 · Price targets 0May 2025 · Ratings 0 · Price targets 0Jun 2025 · Ratings 0 · Price targets 0Jul 2025 · Ratings 0 · Price targets 0Aug 2025 · Ratings 0 · Price targets 0Sep 2025 · Ratings 0 · Price targets 0Oct 2025 · Ratings 1 · Price targets 0Nov 2025 · Ratings 0 · Price targets 0Dec 2025 · Ratings 0 · Price targets 0Jan 2026 · Ratings 0 · Price targets 0Feb 2026 · Ratings 0 · Price targets 0Mar 2026 · Ratings 0 · Price targets 0Apr 2026 · Ratings 0 · Price targets 0May 2026 · Ratings 0 · Price targets 0Jun 2026 · Ratings 0 · Price targets 0Jul 2026 · Ratings 0 · Price targets 0Aug 2026 · Ratings 0 · Price targets 0Sep 2026 · Ratings 0 · Price targets 0
Oct '24Oct '25Sep '26

Most covered24M

StockRatingTargetActionsLast action
SBFMSunshine Biopharma, Inc.Buy2Oct 8

Recent actions

StockRating actionRatingDate
Sunshine Biopharma, Inc.SBFMReiterateBuyOct 8, 2025
Sunshine Biopharma, Inc.SBFMReiterateBuyDec 5, 2024
Sharps Technology, Inc.STSSReiterateBuyMay 9, 2023
GigaCloud Technology Inc.GCTReiterateBuyMar 20, 2023
GigaCloud Technology Inc.GCTReiterateBuyOct 3, 2022
Evogene Ltd.EVGNReiterateBuySep 12, 2022
DarioHealth Corp.DRIOReiterateBuyAug 18, 2022
Immunic, Inc.IMUXReiterateBuyAug 8, 2022
Postal Realty Trust, Inc.PSTLReiterateBuyJun 14, 2022
Oramed Pharmaceuticals Inc.ORMPReiterateBuyMay 16, 2022
DarioHealth Corp.DRIOReiterateBuyMay 16, 2022
Trevi Therapeutics, Inc.TRVIReiterateBuyMar 29, 2022

References

  1. Aegis Capital Corp. Announces the Hiring of a New Managing Director (March 2026)aegiscapcorp.com
  2. AEGIS CAPITAL CORP. – FINRA BrokerCheckbrokercheck.finra.org
  3. FINRA Disciplinary and Other Actions, October 2015 (Aegis Capital $950,000 fine)finra.org
  4. Broker-Dealer Admits It Failed to File SARs (SEC, 2018)sec.gov
  5. Aegis Capital Corp. Letter of Acceptance, Waiver and Consent (FINRA, 2021)finra.org
  6. Aegis Capital research report on Sunshine Biopharma with disclosures (April 2026)sunshinebiopharma.com